ELDN Eledon Pharmaceuticals
- 3.020
- +0.220+7.86%
- 3.120
- +0.100+3.31%
Eledon Pharmaceuticals News
Eledon Pharma Analyst Ratings
Eledon Pharmaceuticals' Tegoprubart Shows Promising Trial Results and Fuels Buy Rating
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)
Eledon Pharmaceuticals' Tegoprubart Shows Promising Clinical Advancements, Reinforcing Buy Rating and Elevated Price Target
HC Wainwright & Co. : The Eledon Pharma (ELDN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $16.00.
Eledon Pharma Analyst Ratings
Eledon Pharma Analyst Ratings
Eledon Pharmaceuticals: A Buy Rating on Breakthrough Organ Transplant Solutions
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX), Edgewise Therapeutics (EWTX) and Eledon Pharmaceuticals (ELDN)
HC Wainwright & Co. Reiterates Buy on Eledon Pharma, Maintains $13 Price Target
Eledon Pharma Analyst Ratings
Eledon Pharmaceuticals Receives Buy Rating: Successful Tegoprubart Trials & Strong Financial Status Contribute to Positive Outlook
Promising Results and Buy Rating for Eledon Pharmaceuticals: Tegoprubart's Potential in Kidney Transplant Therapy
Promising Phase Ib Study Results Bolster Buy Rating for Eledon Pharmaceuticals: An Analysis by Rami Katkhuda
HC Wainwright & Co. Maintains Buy on Eledon Pharma, Lowers Price Target to $13
Eledon Pharma Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Shockwave Medical (SWAV), Eledon Pharmaceuticals (ELDN)
Noble Capital Markets Initiates Coverage On Eledon Pharma With Outperform Rating, Announces Price Target of $10
Eledon Pharma Analyst Ratings
Promising Clinical Trials and Future Projections Bolster Buy Rating for Eledon Pharmaceuticals
Analysis
Price Target
No Data
